Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,828,235
  • Shares Outstanding, K 41,731
  • Annual Sales, $ 337,280 K
  • Annual Income, $ -470 K
  • 60-Month Beta 1.16
  • Price/Sales 4.60
  • Price/Cash Flow 45.97
  • Price/Book 5.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.19
  • Number of Estimates 6
  • High Estimate 0.28
  • Low Estimate 0.13
  • Prior Year 0.28
  • Growth Rate Est. (year over year) -32.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.95 +4.43%
on 01/13/20
46.63 -6.05%
on 12/26/19
-2.42 (-5.23%)
since 12/24/19
3-Month
37.25 +17.61%
on 11/07/19
47.42 -7.61%
on 12/20/19
+4.83 (+12.39%)
since 10/24/19
52-Week
34.64 +26.47%
on 09/09/19
49.50 -11.49%
on 05/03/19
+5.10 (+13.17%)
since 01/24/19

Most Recent Stories

More News
Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.8%

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

PCRX : 43.81 (-0.30%)
HRTX : 22.60 (-3.42%)
New Strong Buy Stocks for January 21st

New Strong Buy Stocks for January 21st

WRB : 72.07 (+0.97%)
PCRX : 43.81 (-0.30%)
MUR : 23.80 (-1.69%)
CURO : 10.32 (-1.43%)
AER : 60.09 (-1.67%)
Pacira BioSciences Launches National Regional Anesthesia Training Initiative with Envision Physician Services

Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians...

PCRX : 43.81 (-0.30%)
ASRT or PCRX: Which Is the Better Value Stock Right Now?

ASRT vs. PCRX: Which Stock Is the Better Value Option?

ASRT : 1.12 (-4.27%)
PCRX : 43.81 (-0.30%)
Pacira BioSciences Reports Full-Year 2019 Preliminary Revenue of $421.0 Million

Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net revenue of $421.0 million for 2019, a 25% increase...

PCRX : 43.81 (-0.30%)
Pacira's (PCRX) Exparel Meets Key Goals in C-Section Study

Pacira's (PCRX) phase IV CHOICE study on its lead drug Exparel in patients undergoing Cesarean section attains the primary as well as key secondary endpoints.

JNJ : 148.32 (-0.14%)
DERM : 18.71 (-0.27%)
PCRX : 43.81 (-0.30%)
VRCA : 15.29 (-9.31%)
Pacira BioSciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 38 Annual J.P. Morgan Healthcare Conference at 9:30 AM PT (12:30 PM ET) on Wednesday, January 15, 2020. Live audio of...

JPM : 133.15 (-2.48%)
PCRX : 43.81 (-0.30%)
Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study

Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.

CORT : 13.06 (-0.57%)
PCRX : 43.81 (-0.30%)
ACRX : 1.75 (+2.34%)
SLNO : 3.64 (-5.45%)
EXPAREL Achieves Primary and Key Secondary Endpoints in Phase 4 CHOICE Study in Cesarean Section Patients

Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that its Phase 4 study of EXPAREL (bupivacaine liposome injectable suspension) in patients undergoing Cesarean section (C-section) achieved its primary...

PCRX : 43.81 (-0.30%)
SmarTrend Watching for Potential Rebound in Shares of Pacira Pharmaceu After 1.64% Loss

Pacira Pharmaceu (NASDAQ:PCRX) traded in a range yesterday that spanned from a low of $44.39 to a high of $45.69. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of...

PCRX : 43.81 (-0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade PCRX with:

Business Summary

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira Pharmaceuticals, Inc....

See More

Key Turning Points

2nd Resistance Point 45.31
1st Resistance Point 44.56
Last Price 43.81
1st Support Level 43.36
2nd Support Level 42.91

See More

52-Week High 49.50
Fibonacci 61.8% 43.82
Last Price 43.81
Fibonacci 50% 42.07
Fibonacci 38.2% 40.32
52-Week Low 34.64

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar